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Abstract
Purpose Sporadic desmoid-type fibromatosis (DTF) is a rare, chronic, non-metastasising, disease of the soft tissues. It is 
characterised by local invasive and unpredictable growth behaviour and a high propensity of local recurrence after surgery 
thereby often having a great impact on health-related quality of life (HRQL). This study aims to review currently used HRQL 
measures and to asses HRQL issues among DTF patients.
Methods A mixed methods methodology was used consisting of (1) a systematic literature review, according to the PRISMA 
guidelines (2009), using search terms related to sporadic DTF and HRQL in commonly used databases (e.g. Embase, Medline 
Ovid, Web of science, Cochrane Central, Psyc Info, and Google scholar), to provide an overview of measures previously used 
to evaluate HRQL among DTF patients; (2) focus groups to gain insight into HRQL issues experienced by DTF patients.
Results The search strategy identified thirteen articles reporting HRQL measures using a wide variety of cancer-specific 
HRQL tools, functional scores, symptom scales (e.g. NRS), and single-item outcomes (e.g. pain and functional impairment). 
No DTF-specific HRQL tool was found. Qualitative analysis of three focus groups (6 males, 9 females) showed that partici-
pants emphasised the negative impact of DTF and/or its treatment on several HRQL domains. Six themes were identified: 
(1) diagnosis, (2) treatment, (3) follow-up and recurrence, (4) physical domain, (5) psychological and emotional domain, 
and (6) social domain.
Conclusion A DTF-specific HRQL tool and consensus regarding the preferred measurement tool among DTF patients is 
lacking. Our study indicates that HRQL of DTF patients was negatively affected in several domains. A DTF-specific HRQL 
measure could improve our understanding of short- and long-term effects and, ideally, can be used in both clinic and for 
research purposes.
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Introduction
Desmoid-type fibromatosis (DTF) is a soft tissue tumour that 
arises from musculoaponeurotic structures. It is incapable of 
metastasising and is often described as a benign tumour in 
clinical practice. However, due to its local aggressive behav-
iour and its known tendency of local recurrence after initial 
surgical resection, it is categorised as a borderline tumour [1]. 
Desmoid-type fibromatosis is rare, with a reported incidence 
of 5.4 new cases per million persons per year in the Dutch 
population [2]. Symptoms vary, depending on tumour location 
and size, and can be very severe. Roughly two types can be dis-
tinguished: sporadic DTF with extra-abdominal or abdominal 
wall tumour formation and familial adenomatous polyposis 
(FAP)-related DTF with intra-abdominal tumour formation 
[3, 4].
The aetiology of sporadic DTF remains doubtful although 
a history of trauma has been reported, as well as specific hor-
monal status (such as pregnancy) and genetic predisposition 
[5–8]. With local recurrence rates up to 50%, potential treat-
ment benefits and adverse effects of treatment should be con-
sidered carefully [9–11]. Nowadays, active surveillance is rec-
ommended in asymptomatic patients, while treatment options 
for symptomatic patients include surgical resection, radiation 
therapy, and systemic therapy [12–16]. Determination of treat-
ment effectiveness is currently mainly evaluated by tumour 
size or recurrence free survival [11, 17, 18]. Although such 
end-points can be appropriate in malignant diseases, the unpre-
dictable growth behaviour including spontaneous regression 
and the low mortality rate of sporadic DTF renders such out-
comes less appropriate for this borderline disease [16]. Con-
sequently, the question rises whether health-related quality of 
life (HRQL) assessment could be a more appropriate outcome 
measure in DTF [10, 14, 19, 20]. The definition of HRQL is 
“a patients’ evaluation of the impact of a health condition and 
its treatment on all relevant aspects of life”. Patient-reported 
outcome measures (PROMs) can be used to measure HRQL 
with various purposes: screening tools, method for identifying 
patient preferences, to guide clinicians for informed decision 
making, to improve patient-provider communication, and to 
assess the efficacy of treatments in the context of clinical tri-
als [21]. In DTF, few researchers have sought to understand 
patient’s perceptions on the disease, and HRQL is not (yet) 
widely accepted as an appropriate outcome measure. The aim 
of this mixed-method study is to explore currently used HRQL 
tools and identify HRQL issues of DTF patients.
Methods
Literature review
The literature review was conducted in accordance with 
the PRISMA guidelines [22]. A systematic literature 
search with terms related to sporadic DTF and HRQL 
(Appendix 1) was conducted by an expert research librar-
ian on 6 November 2017 to identify HRQL tools currently 
used among DTF patients. No language or publication 
limitations were applied. Used databases were Embase, 
Medline Ovid, Web of science, Cochrane Central, Psyc 
Info, and Google scholar. The resulting publications were 
analysed using inclusion and exclusion criteria at two lev-
els: title/ abstract (1) and full text (2) by two reviewers 
(MJMT and OH). Data from papers that met the inclusion 
criteria at full-text level were extracted for final inclusion 
by one reviewer [MJMT] (Appendix 2). Corresponding 
authors were contacted in case of lack of availability of 
full text, and three authors granted our request. Vari-
ables that were identified in included papers were number 
of patients, number of patients for which PROMs were 
available, tumour location, treatment, PROM outcome 
pre-treatment, and PROM outcome post-treatment. The 
outcome of each study was reported according to the spe-
cific PROM used in the study.
Patient recruitment
To identify the HRQL issues of DTF patients, focus 
group sessions were organised. Patients diagnosed with 
sporadic DTF were recruited from the Erasmus Medical 
Centre (MC) in Rotterdam, the Netherlands. As FAP-
associated DTF patients are also confronted with many 
other issues compared to patients with sporadic DTF, these 
patients were excluded. Eligible patients were diagnosed 
with DTF, regardless of their stage of disease (e.g. pre-
treatment or during follow-up), previous or current treat-
ments, and site of disease. Additionally, they had to be 
above the age of 18 at the time of the focus group and 
participation required sufficient Dutch language skills. 
Patients with a recent diagnosis of cancer were excluded 
since this diagnosis might influence their HRQL. Poten-
tial participants were approached by telephone, with a 
maximum of four attempts to explain the study objectives 
and received a written invitation and information letter. 
In total, three focus groups were organised in July and 
August 2017: one with male participants, one with female 
participants, and one mixed sex group. The decision to 
organise separate sessions for both sexes was based on 
the assumption that patients would be more likely to share 
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personal experiences or feelings with the same sex. The 
third, mixed sex group was organised separately because 
of logistic reasons. The focus group sessions took place 
in the Erasmus MC. Written informed consent (including 
permission for making field notes and audio recording for 
anonymous processing) and background information was 
obtained at the start.
Data collection
The focus group sessions were supervised by the first author 
[MJMT]; a second independent researcher kept written 
records and was not actively involved in the discussions. A 
pre-prepared protocol, based on the protocol of Husson et al. 
(2018, manuscript submitted) was used for guidance (Fig. 1).
Participants received a brief introduction with the 
explanation of the study objectives and an opening ques-
tion for introduction was answered by each participant. 
Next, pre-prepared exploratory questions developed spe-
cific for the objectives of this study were asked to encour-
age conversation and discussion. Transition questions were 
asked to explore several aspects of HRQL issues around 
the time of diagnosis, treatment, and follow-up. The focus 
groups lasted 1.5–2 h, and an exit question was used to ter-
minate the focus group. Participants received an evaluation 
form and 15 euro gift certificate in order to express our 
appreciation for their participation. Focus group sessions 
were audio recorded, and transcribed by the first author 
[MJMT]. ATLAS.ti 8.0© (Scientific Software Develop-
ment GmbH, Berlin, Germany) was used for generating 
codes for themes and subthemes. The field notes were used 
as complementary data to transcripts as they described 
non-verbal communication of participants. Data were 
ordered into relevant code terms and then categorised into 
themes by two researchers [MJMT and OH] and analysed 
independently. Consensus was reached through continuous 
discussion. Relevant quotes of focus group participants 
were selected to support findings.
Approval from the Medical Ethics Committee of Eras-
mus MC in Rotterdam, the Netherlands was obtained for 
this study (file number MEC-2017-269). All patients gave 
written informed consent before the start of the focus 
groups and patient’s anonymity and confidentiality were 
ensured throughout the study by the use of study codes 
replacing identifying information. Only the first author 
had direct access to the digital record of study codes and 
patient information.
Fig. 1  Focus group guideline Opening question 
- Can you introduce yourself by telling your name, age and place of residence and tell us shortly about the location 
of your DTF tumour, which treatments you had and what the current status is.
(This question was asked  in to every participant at the start of the focus group)
Transition questions
Moment of diagnosis
- Can you share your experience around the moment of diagnosis?
- Can you share your experience about the referral to this specialised centre?
- What kind of feelings did you experience when you were first diagnosed?
- How was the information about DTF in the first period?
- Can you remember the expectations that you had when you visited the specialist for the first time?
- How did your family and friends react? Did you need any support? Did you receive this support?
- Can you explain how you were informed about the treatment?
Symptoms
- Did you experience any problems on physical, emotional, social and/or financial level?
- How do / did you cope with your symptoms?
- Did you have to adjust your way of life? I yes, in what manner?
- Did you receive any support from your family and friends?
- How did you experience your contact with your treating specialist?
- How did you experience the professional support during the course of disease?
- How did you experience the amount of information about the disease and the treatment(s)?
Treatment
- Can you tell us what kind of treatment(s) you received?
- Can you tell us how the treatment(s) affected your life?
Work/ finances
- How did the disease effect your work and financial situation?
Key questions
- Which symptoms do you associate with your primary treatment(s)?
- Which symptoms do you experience during your follow-up?
- Which symptoms, caused by the desmoid tumour, do you experience on the long term?
- Which symptoms, caused by the desmoid tumour, have the most impact on your life?
Exit questions
- Can you describe your feelings when we are discussing your disease?
- Can you describe your feelings about this discussion?
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Results
Literature review
A systematic literature search (Appendix 1) showed 3114 
articles after deduplication. In total, 3067 articles were 
excluded based on title or abstract. Full-text reviewing 
took place for the remaining 47 articles excluding another 
34 articles (flow chart Appendix 2). Thirteen articles 
describing seven validated scoring systems were identi-
fied. No DTF-specific questionnaires were identified in 
this literature review (Table 1).
The Disabilities of the Arm, Shoulder and Hand 
(DASH) score is a 30-item questionnaire designed to 
evaluate disability of the upper limb region by measur-
ing symptoms and physical functions with 5 response 
options and higher scores reflecting greater disability 
[23–26]. The Enneking/Musculoskeletal Tumor Society 
(MSTS) score comprises six categories: pain, function, 
and emotional acceptance of both lower and upper extrem-
ities, support, walking, and gait of the lower extremities, 
and hand positioning, dexterity, and lifting ability in the 
upper extremity, for which patients have to assign values 
ranging from 0 to 5 points. Higher values indicate better 
functioning [24, 27–30]. The European Organisation for 
Research and Treatment of Cancer quality of life ques-
tionnaire C30 (EORTC QLQ-C30) is a 30-item, cancer-
specific questionnaire designed for evaluating quality of 
life incorporating five functional scales, symptom scales, 
and global health and quality of life scales [19, 31]. The 
MD Anderson Symptom Inventory (MDASI) measures 
the severity of 13 cancer-related symptoms experienced 
by the patient during the previous 24 h. The score rates 
symptoms on an 11-point scale; higher scores reflect more 
severe symptoms [32, 33]. The (modified) Johnstone scale 
provides a functional grading system with grades rang-
ing from 0 to 4; higher scores reflect fewer limitations 
[34, 35]. The Numerical Rating Scale (NRS) is used for 
self-reporting subjective conditions, currently in use for 
several symptoms. Symptoms are rated on a 0–10 scale; 
higher scores reflect more severe symptoms [36–38]. The 
Toronto Extremity Salvage score (TESS) is internation-
ally used for measuring functional outcome and physical 
disability in patients with extremity tumours undergoing 
limb preservation surgery. This questionnaire consists of 
29 (upper extremity) or 30 (lower extremity) questions 
regarding daily activities. Each item is rated on a scale 
from 1 to 5; higher values represent better function [28, 
39, 40].
Other identified measures and questionnaires included 
items related to functional impairment, pain, and cosmetic 
outcome (Table 1) [41–43].
Focus group
In total, 45 patients were approached to participate; 22 
patients agreed to receive written information, and 15 
patients could not be reached by telephone. Reasons for 
refusal included not willing to participate in a group experi-
ence but willing to do a personal interview, not available at 
pre-set dates, language barrier, or not willing to participate 
because of minimal symptoms. A total of 15 patients partici-
pated in the focus groups. The first group consisted of five 
female participants with a median age of 37 years (range 
25–60 years), the second group consisted of five male par-
ticipants with a median age of 62 (range 37–75 years), and 
the third group was a mixed sex group with a median age of 
37 years (range 36–53 years). Participants differed in age at 
diagnosis, education level, and treatment (Table 2). None of 
the participants knew another person with the same condi-
tion before the focus group. Most participants were treated 
surgically (n = 8) or received a conservative management 
(n = 4). Three participants received a combination of thera-
pies. A minority of the participants sought support in the 
paramedic field (e.g. physiotherapist, occupational therapist, 
social worker, and dietician).
Qualitative analysis
HRQL issues were categorised into six themes: (1) diagno-
sis, (2) treatment, (3) follow-up and recurrence, (4) physical 
domain, (5) psychological and emotional domain, and (6) 
social domain. The themes were further categorised into 
subthemes. An overview of themes, subthemes, key issues, 
and quotes is provided in Table 3.
Diagnosis
Almost all participants reported feelings of uncertainty and 
anxiety of having cancer during the period of waiting on 
their final diagnosis. They described this as having a great 
impact on their overall life. Upon diagnosis, feelings of relief 
are described due to the borderline nature of this disease. 
Participants with more symptoms and a more aggressive 
clinical course of DTF mentioned being frustrated about 
underestimation of the consequences since the disease is 
categorised as a borderline tumour and can act in a more 
malignant way with sometimes severe sequelae compared 
to benign tumours. The opinion on receiving information 
about DTF varied among participants. Some participants felt 
they did not receive enough information from their treating 
physician, some participants searched for more information 
on internet or asked their general practitioner, and some 
deliberately did not search on the internet because of fear to 
find unpleasant information. Most participants agreed that 
the amount and depth of information they found in general 
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Table 2  Characteristics of 
fifteen focus group participants Number of patients (%) Age in years (range)
Sex
 Male 9 (60%)
 Female 6 (40%)
Age at time of focus group
 Median (range) years 46 (25–75)
Age at time of diagnosis
 Median (range) years 43 (16–75)
Marital status
 Single 3 (20%)
 Married 9 (60%)
 Partnership 2 (13%)
 Windowed 0 (0%)
 Divorced 1 (7%)
Nationality
 Dutch 14 (93%)
 Other 1 (7%)
Highest completed education
 Elementary education 1 (7%)
 Secondary education 2 (13%)
 Middle-level applied education 3 (20%)
 Higher professional education 6 (40%)
 Scientific education (university) 1 (7%)
 Missing value 2 (13%)
Current paid employment
 Yes 8 (53%)
 No 5 (33%)
 Retired 2 (13%)
Familiar with DTF before diagnosis
 Yes 0 (0%)
 No 15 (100%)
Location of DTF
 Head/neck 1 (7%)
 Upper extremity/shoulder 2 (13%)
 Thoracic wall 0 (0%)
 Abdominal wall 4 (27%)
 Back 1 (7%)
 Retroperitoneal/intra-abdominal 2 (13%)
 Hip/pelvis/gluteal region 2 (13%)
 Lower extremity 3 (20%)
Received treatment(s)
 Conservative management 4 (27%)
 Surgery 8 (53%)
 Radiation therapy 0 (0%)
 Systemic therapy 0 (0%)
 Combination of  therapiesa 3 (20%)
Contact with healthcare professionals
 Physiotherapist/occupational therapist 5
 Dietician 1
 Social worker 2
 Psychologist 1
 Pain specialist 1
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was not satisfying. This observation was substantiated by 
multiple questions from participants about DTF during the 
group sessions.
Treatment
Participants with minor symptoms and solely treated with 
surgery reported being glad or relieved that the tumour was 
removed as they had the feeling that it “did not belong to 
their body”. One participant with major symptoms from an 
intra-abdominal tumour felt that surgery was the only treat-
ment option, but feared for a stoma or dying during surgery. 
Participants with a conservative management reported to 
be satisfied since they had minor symptoms and potentially 
mutilating surgery could be avoided.
Follow‑up and recurrence
A common theme in the qualitative study was fear of recur-
rence or worries about the future and future health. Not all 
participants were correctly informed about the risk on local 
recurrence. Feelings of uncertainty remained present during 
follow-up because of the knowledge that the tumour may 
be able to recur. One participant with DTF localised in the 
lower extremity reported struggle with weakness in the leg 
due to previous treatments, which made her fearful of the 
future.
Physical domain
The most common symptoms before diagnosis are described 
in Table 2. Complications of treatment included infection of 
the surgical wound and severe neuropathic pain due to nerve 
damage. Residual issues after treatment regarded scars, 
being asymmetrical, having function restrictions, oedema, 
stiffness, lack of sensibility, and muscle weakness. One par-
ticipant used a wheelchair and crutches due to a lower leg 
amputation, and another patient used an electric wheelchair 
due to severe neuropathic pain after being treated surgi-
cally. One participant reported that physical therapy was not 
offered to her, but in retrospect she would have appreciated it 
since she experiences weakness of the affected limb.
Emotional/psychological domain
Participants expressed that “they felt they did not have a 
choice” and “they will face the situation as it comes” and 
learned how to deal with their problems over time. Life-style 
changes included minor adjustments because of functional 
limitations and major adjustments including movement to a 
ground floor apartment. One participant reported that DTF 
restricted her from having another child, which had a major 
impact on her family. One participant reported a low self-
esteem and problems with body image due to scars. Another 
participant reported the feeling that he missed out on starting 
a family because of extensive treatments which started at a 
young age. One participant was treated by a psychologist. 
Several participants stressed that they felt differently about 
life after diagnosis and stated to be more grateful for their 
life compared to the time before the diagnosis.
Social domain
Participants reported that DTF had influenced their working 
life, as they had to stop working temporarily after treatment. 
This period ranges from a couple of weeks to two years 
and in one case not being able to work at all. Participants 
reported that the uncertainty during the time of diagnosis 
Table 2  (continued) Number of patients (%) Age in years (range)
 Home care/nursing care 1
 Otherb 1
Self-reported  symptomsc
 Lump with obvious growth 10
 Pain 3
 Tumour complains during daily  activities 8
 Functional limitations (before treatment) 3
Self-reported medical  historyc
 Surgery related desmoid 6
 Desmoid related to hormonal status 3
a n = 1 surgical resection with post-operative radiotherapy, n = 1 surgical resection, radiotherapy, and iso-
lated limb perfusion (ILP), n = 1 surgical resection (with final amputation of the lower leg, radiotherapy, 
ILP, hormonal therapy, experimental chemotherapy)
b Lymphatic therapy
c Obtained during the focus group sessions as reported by the patients
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and the fear of cancer influenced their family life. Several 
participants mentioned to downstage their problems since 
they did not want to be a burden to their families or they 
wanted to protect their loved ones. One participant reported 
that social relationships changed after the diagnosis. Some 
friendships became closer and some friendships had ended 
due to lack of support. She specifically mentioned that her 
friends paid less attention to her disease and health status 
because of the term ‘benign disease’ which implies minor 
disease-related issues or short course of disease.
Discussion
With this study, we aimed to gain more insight in HRQL 
issues and currently used HRQL tools in the setting of DTF. 
The results of this study can be seen as the first step towards 
developing a disease-specific HRQL tool that can be used in 
clinical practice or research. The literature review identified 
several non-disease-specific HRQL tools; no tool currently 
exists that assesses all issues relevant for DTF patients. 
Functional scores like the DASH score [26], the Enneking 
score/MSTS [24, 27, 28, 30], the TESS [28], and the John-
stone scale [34] are used for extremity diseases but are not 
suitable for patients who have sites of disease other than the 
extremities. Symptoms scores including the MDASI score 
[32] and the NRS [37, 38] are quite specific for measuring 
the severity of symptoms, and could be useful in combina-
tion with HRQL tools measuring issues like emotional or 
social well-being. The EORTC QLQ-C30 [19] is designed to 
cover issues relevant for cancer patients and may be a good 
generic measure to be completed by an item list consisting 
of the key DTF-specific issues identified in our focus groups, 
in order to create a more holistic perspective of HRQL issues 
in patients with DTF.
The results of the literature review show that researchers 
are interested in measuring the effect of DTF and its treat-
ment on functioning or pain, but no consensus exists with 
respect to the preferred tool, as a DTF-specific tool has not 
been developed yet. One could argue that a combination 
of the aforementioned scores could be sufficient to get a 
clear view of relevant issues of DTF patients. A downside 
to this might be that patients are exposed to a large number 
of questions, which could be non-relevant and give patients 
an additional burden. A carefully developed DTF-specific 
tool could be effective in measuring HRQL.
There are limitations to the current systematic literature 
review. Since DTF is a rare soft tissue tumour, included 
studies comprise retrospective, small-sized studies with low 
methodologic quality. Additionally, risk of bias could not be 
assessed properly.
To create a HRQL tool which is suitable for DTF patients 
and to achieve at least satisfying content validity, focus Ta
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groups were used which encouraged participants to discuss 
their views on HRQL issues [44]. Our focus group results 
suggest that patients with DTF often face problems with rec-
ognition and management because of the lack of diagnostic 
awareness, as a result of its rarity, and because of the strik-
ing discrepancy between its benign histological appearance 
and its local aggressive behaviour. This study identified key 
issues in six themes: (1) diagnosis, (2) treatment, (3) follow-
up and recurrence, (4) physical domain, (5) psychological 
and emotional domain, and (6) social domain, which will 
be the basis of a future DTF-specific tool. The first three 
themes (diagnosis, treatment, and follow-up and recurrence) 
can be clustered as “the process of healthcare” and the last 
three themes (physical domain, psychological and emotional 
domain, and social domain) can be clustered as “symptoms 
and function”. We do acknowledge the overlap that can 
occur between themes.
The need to gain more insight into HRQL of DTF patients 
is reflected by several attempts made around the world. In 
the USA, the Desmoid Tumor Research Foundation (DTRF) 
patient registry opened recently (September 2017) to reg-
ister clinical, pathological, and geographical variables of 
DTF patients. Additionally, a survey, based on both vali-
dated and non-validated HRQL questionnaires, was put 
together to gain more insight in HRQL of DTF patients 
[45]. The latter, a PRO-specific DTF tool, was presented 
on the Annual Meeting of the American Society of Clini-
cal Oncology of 2017 [46]. In the Royal Marsden UK, two 
focus group sessions took place in March 2017 (Husson 
et al. 2018, manuscript submitted). This resulted in four key 
themes (diagnostic pathway, treatment pathway, living with 
DTF, supportive care). We found an interesting difference in 
the impact of DTF between the Dutch and UK focus group 
participants. Apart from the selection bias, which could be 
explained by the selection of patients and the willingness 
of patients to participate in such a study, and differences in 
the way patients had been treated with more often chemo-
therapy (Caelyx) in the UK focus group, other factors may 
play a role, which are beyond the individual patient level 
of these focus group participants. An international desmoid 
population-based questionnaire study could ideally give 
more detailed information. Such a study could also exam-
ine which patients are particularly at risk for poor disease-
related outcomes on their quality of life.
Our focus group study has several limitations. First, the 
recruitment of participants for focus group sessions might 
have led to selection bias. Patients who are introvert, or 
who have minor symptoms, or received successful treat-
ment might have been less likely to agree to participate in 
a focus group session and vice versa. A frequently heard 
response, when being approached for participation, was 
the worry about being influenced by negative experiences 
of other patients. However, in that case, most patients 
were willing to do a private face-to-face interview with 
the author to share their experiences. This suggests that 
not all patients feel comfortable to join a group session. 
The second limitation involves the small number of DTF 
patients. Due to the rarity of DTF, larger sample sizes are 
difficult to obtain in a single-centre study. Nevertheless, 
the small sample size gave all participants enough time to 
share their experiences [44]. The third limitation comprises 
the heterogeneity of the focus group participants, since we 
did not select participants based on their stage of disease 
or their treatment. Only one out of fifteen participants 
received previous systemic treatment, which might be an 
underestimation of the total percentage of patients in the 
DTF population receiving medication. We do acknowledge 
that every treatment modality (e.g. surgery, radiotherapy, 
chemotherapy) could impact HRQL on the short- and the 
long-term. However, regardless of previous treatments, 
patients, included in the focus groups, shared a wide vari-
ety of experiences coinciding with the chronic nature of 
the disease. This resulted in the report of various HRQL 
issues, which we believe do represent the entire spectrum 
of HRQL issues experienced by the DTF population.
To our knowledge, this is one of the few studies that 
explored currently used HRQL tools and the experi-
ence of HRQL issues in the setting of sporadic DTF. The 
strength of our study is the approach according to the 
EORTC guidelines for developing questionnaire modules 
[47]. By conducting the systematic literature review, we 
revealed the necessity for measuring HRQL outcomes in 
clinical practice and exposed a deficit in suitable HRQL 
tools for this patient group. The focus group approach 
elicits patients to explore and to clarify individual and 
shared perspectives. This resulted in the identification of 
key issues experienced by DTF patients and ensures the 
achievement of high content validity.
The results of the systematic literature review and the 
focus group sessions will be used to create a provisional 
list of issues which will be ranked by both patients and 
healthcare professionals for their relevance. Next, an item 
list will be created which will form the basis of the DTF-
specific tool. This tool could complement the EORTC 
QLQ-C30 questionnaire with questions capturing issues 
raised from the focus groups, such as concerns about 
recurrences and emotional or psychological problems, 
and site-specific issues (i.e. extremity, abdominal wall). 
This questionnaire is much needed in order to understand 
effects of DTF and its treatment on patient-reported out-
comes and provide support for patients who experience 
problems regarding physical, emotional, social, and psy-
chological well-being. Also, knowledge about HRQL 
outcomes can be used for informed decision making dur-
ing the diagnosis and treatment trajectory of this patient 
group.
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Conclusion
A DTF-specific tool and consensus regarding the preferred 
measurement tool for measuring HRQL in DTF patients is 
lacking in the literature. Used questionnaires either focus on 
single items, excluding possible items of significance, or are 
too generic. Existing questionnaires could be complemented 
with questions regarding key HRQL issues, identified during 
the focus group sessions, which DTF patients experience in 
various HRQL domains. This DTF-specific tool, validated in 
a large population study, would provide guidance for clinical 
practice, can compare treatment effects on HRQL and raise 
awareness of the impact of DTF on patients’ life.
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Appendix 1: Literature search 6 November 
2017 (Embase.com)
(‘desmoid tumor’/exp OR Fibromatosis/exp OR ‘famil-
ial colon polyposis’/exp OR (desmoid* OR Fibromatos* 
OR ((familial* OR heredit* OR genetic* OR Adenoma-
tous*) NEAR/6 polypos*)):ab,ti) AND (‘quality of life’/
exp OR ‘quality of life assessment’/exp OR ‘functional 
assessment’/exp OR ‘general health status assessment’/
exp OR ‘health status’/exp OR ‘health impact assessment’/
de OR ‘daily life activity’/exp OR ‘ADL disability’/exp 
OR ‘patient satisfaction’/exp OR ‘distress syndrome’/exp 
OR ‘stress’/exp OR emotion/exp OR ‘sexuality’/exp OR 
‘self concept’/exp OR ‘family relation’/exp OR ‘family 
life’/exp OR ‘coping behavior’/exp OR ‘disability’/de 
OR invalidity/de OR ‘immobility’/de OR ‘esthetics’/de 
OR ‘pain assessment’/exp OR ‘pain measurement’/de OR 
‘social interaction’/exp OR ‘social life’/exp OR ‘social 
environment’/de OR ‘psychosocial environment’/de OR 
‘social support’/de OR ‘social stress’/de OR ‘social rejec-
tion’/de OR ‘mental health’/exp OR ‘wellbeing’/exp OR 
‘interview’/exp OR ‘questionnaire’/exp OR ‘assessment of 
humans’/exp OR ‘psychological aspect’/exp OR ‘psychol-
ogy’/exp OR ‘marriage’/exp OR ((quality NEAR/3 life) 
OR hrql OR qol OR (Functional* NEAR/3 (outcome* 
OR asses*)) OR (daily NEAR/3 (life OR living)) OR 
ADL OR (patient NEAR/3 satisf*) OR ((health OR func-
tion*) NEAR/3 status*) OR eortc OR ((short-form OR sf) 
NEXT/1 (12 OR 20 OR 36)) OR sf12 OR sf20 OR sf36 
OR distress OR (stress NEAR/3 (patient* OR personal* 
OR psycho* OR mental* OR life)) OR emotion* OR anxi* 
OR sexual* OR (self NEXT/1 (concept* OR esteem OR 
satisf* OR percept*)) OR body-image* OR burden* OR 
((impact* OR problem* OR issue*) NEAR/6 (function* 
OR disease* OR personal* OR psycholog* OR body OR 
clinical* OR health* OR life OR daily OR tumor* OR 
tumour* OR social*)) OR psychosocial* OR worry* OR 
worrie* OR ((family OR interpersonal OR partner* OR 
spous*) NEAR/6 (relation* OR communicat* OR life OR 
involve*)) OR coping OR ((adaptive* OR adjustment*) 
NEAR/6 (behav* OR psycho*)) OR impairment* OR 
disabilit* OR invalidit* OR esthetic* OR aesthetic* OR 
cosmetic* OR beauty OR fitness OR (physical* NEAR/3 
(condition* OR mobility)) OR immobility OR (pain* 
NEAR/6 (assess* OR inventor* OR measure*)) OR attrac-
tiveness* OR (social* NEAR/3 (isolat* OR distan* OR 
interact* OR life* OR support OR reject* OR participat* 
OR environment*)) OR feeling* OR (mental NEAR/3 
(health OR status OR suffer*)) OR wellbeing OR well-
being OR insecur* OR resilien* OR (symptom* NEAR/6 
(assess* OR inventor* OR check*)) OR karnofsk* OR 
(karno* NEXT/3 (score* OR scale* OR perform* OR 
function* OR stat* OR index* OR rating)) OR (focus 
NEAR/3 group*) OR interview* OR questionnaire* OR 
(assessment* NEAR/3 human*) OR hopeless* OR fear 
OR frustrat* OR hopeless* OR helpless* OR unhapp* OR 
mood OR uncertaint* OR (lack NEAR/3 informat*) OR 
disturb* OR concerned OR deficit* OR ((self OR patient*) 
NEXT/1 report*) OR marriage*):ab,ti) NOT ([animals]/
lim NOT [humans]/lim).
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Appendix 2: Flow chart showing the selection of studies for the inclusion in the literature 
review
Inclusion criteria:
- patients with sporadic DTF
- original articles
- availability of full text
- the use of (non)validated tool or measurement to measure HRQL 
- language: Dutch, English, German or French.
Exclusion criteria:
Records identified through database 
searching
(n=5373)
Sc
re
en
in
g
In
cl
ud
ed
El
ig
ib
ili
ty
Id
en
tif
ic
at
io
n Additional records identified through 
other sources
(n=0)
Records after duplicates removed
(n=3314)
Records screened
(n=3314)
Records excluded
(n = 3067)
Full-text articles assessed for 
eligibility
(n=47)
Full-text articles excluded, 
with reasons
(n=34)
n=3 STS and DTF combined, 
no subgroups 
n=1 letter to the editor
n=4 case reports 
n=20 no full text available
n=3 no HRQL tool 
n=1 review 
n=1 HRQL of FAP patients
n=1 other languageStudies included in 
quantitative synthesis 
(systematic literature review) 
(n=13)
- case reports, reviews
- FAP patients
n: number of studies
STS: soft tissue sarcoma
DTF: desmoid-type fibromatosis
HRQL: health related quality of life
FAP: familial adenomatous polyposis
The PRISMA IPD low diagram
© Reproduced with permission of the PRISMA IPD Group, which encourages sharing and reuse for non 
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